NUWE Nuwellis, Inc. Stock Quote

NUWE [NASD]

Index	-	P/E	-	EPS (ttm)	-5.26	Insider Own	0.24%	Shs Outstand	6.53M	Perf Week	-37.20%
Market Cap	16.64M	Forward P/E	-	EPS next Y	-2.75	Insider Trans	0.00%	Shs Float	6.52M	Perf Month	-43.11%
Income	-17.50M	PEG	-	EPS next Q	-0.72	Inst Own	22.90%	Short Float	0.77%	Perf Quarter	-37.65%
Sales	8.40M	P/S	1.98	EPS this Y	96.20%	Inst Trans	-28.28%	Short Ratio	0.20	Perf Half Y	-58.86%
Book/sh	3.98	P/B	0.65	EPS next Y	-	ROA	-65.50%	Target Price	-	Perf Year	-73.79%
Cash/sh	3.75	P/C	0.69	EPS next 5Y	-	ROE	-75.30%	52W Range	2.45 - 12.57	Perf YTD	-62.70%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-103.90%	52W High	-79.32%	Beta	1.05
Dividend %	-	Quick Ratio	7.10	Sales past 5Y	163.10%	Gross Margin	53.70%	52W Low	6.12%	ATR	0.31
Employees	64	Current Ratio	7.80	Sales Q/Q	31.60%	Oper. Margin	-	RSI (14)	21.43	Volatility	8.18% 6.15%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	76.70%	Profit Margin	-	Rel Volume	2.73	Prev Close	2.51
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 10 BMO	Payout	-	Avg Volume	247.08K	Price	2.60
Recom	-	SMA20	-35.77%	SMA50	-37.01%	SMA200	-55.17%	Volume	673,539	Change	3.59%

Sep-17-21 04:00PM	Nuwellis, Inc. Announces Closing of $10.0 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option GlobeNewswire
Sep-15-21 08:19AM	Nuwellis, Inc. Announces Pricing of $8.7 Million Underwritten Public Offering of Common Stock GlobeNewswire -27.64%
Sep-14-21 04:03PM	Nuwellis, Inc. Announces Proposed Underwritten Public Offering of Common Stock GlobeNewswire -8.21%
08:00AM	Nuwellis, Inc. Reports An Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-31-21 07:00AM	Nuwellis Inc. to Speak at Upcoming Investor Conferences GlobeNewswire
Aug-24-21 09:00AM	Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-10-21 08:00AM	Nuwellis, Inc. Announces 35 Percent Increase in Revenue for Second Quarter 2021 Over Previous Year and Provides Company Update GlobeNewswire +16.75%
Aug-05-21 08:00AM	Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant GlobeNewswire
Jul-27-21 04:03PM	Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021 GlobeNewswire
Jul-13-21 08:00AM	American Medical Association Issues New CPT Code for Nuwellis Aquadex Ultrafiltration GlobeNewswire +7.83%
Jul-06-21 04:03PM	Nuwellis Inc. to Participate at the 2021 Ladenburg Thalmann Healthcare Conference GlobeNewswire
Jul-01-21 04:00PM	Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-24-21 08:00AM	Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jun-22-21 08:00AM	Nuwellis Announces New Appointments to Leadership Team GlobeNewswire
Jun-01-21 08:00AM	Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration GlobeNewswire +9.70%
May-20-21 04:03PM	Nuwellis, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-17-21 08:00AM	ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure GlobeNewswire -5.76%
May-13-21 08:45AM	Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology GlobeNewswire -5.61%
May-11-21 08:00AM	Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update GlobeNewswire -8.22%
07:15AM	Nuwellis, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-21 04:05PM	Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021 GlobeNewswire

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Brunei, Germany, Greece, Hong Kong, India, Israel, Italy, Palestine, Singapore, Spain, Switzerland, Thailand, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience